High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults.
Supported by experimental evidence and convincing results of early phase II studies, since the 1980s high-dose chemotherapy (HDC) with autologous hematopoietic stem cell support (AHSCT) has been uncritically adopted by many oncologists as a potentially curative option for several solid tumors. As a result, the number (and size) of randomized trials comparing this approach with conventional chemotherapy initiated (and often abandoned before completion) in this setting was limited and the benefit of a greater escalation of dose of chemotherapy with stem cell transplantation in solid tumors remains, with the possible exception of breast carcinoma (BC) and germ cell tumors (GCT), largely unsettled. In this article, we review and comment on the data from studies to date of HDC for solid tumors in adults.
Pedrazzoli
Paolo
P
Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca' Granda, Milano, Italy, and Department of Hematology, Ankara University Medical School, Turkey.
Rosti
Giovanni
G
Secondino
Simona
S
Carminati
Ornella
O
Demirer
Taner
T
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D016190:Carboplatin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D019317:Evidence-Based Medicine; D005260:Female; D018237:Germinoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D016879:Salvage Therapy; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D016190:Carboplatin